Publications by authors named "A Mocroft"
Objectives: Tuberculosis (TB) risk after initiation of antiretroviral treatment (ART) is not well described in a European setting, with an average TB incidence of 25/10 in the background population.
Methods: We included all adult persons with HIV starting ART in the RESPOND cohort between 2012 and 2020. TB incidence rates (IR) were assessed for consecutive time intervals post-ART initiation.
Article Synopsis
- The study explored the impact of newer antiretroviral drugs (ARVs) on chronic liver enzyme elevation (cLEE) in people with HIV who started ARVs after January 1, 2012.
- Over the follow-up period, 11.3% of participants experienced cLEE, with higher rates observed in the first year but no cumulative effect from ARV use over time.
- Notably, the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and tenofovir disoproxil fumarate (TDF) increased the risk of cLEE, while darunavir (DRV) appeared to reduce the risk.
Background: Women with HIV are globally underrepresented in clinical research. Existing studies often focus on reproductive outcomes, seldom focus on older women, and are often underpowered to assess sex/gender differences. We describe CD4, HIV viral load (VL), clinical characteristics, comorbidity burden, and use of antiretroviral therapy (ART) among women with HIV in the RESPOND study and compare them with those of the men in RESPOND.
View Article and Find Full Text PDFPeople with human immunodeficiency virus (HIV) are at risk for chronic kidney disease (CKD) due to HIV and antiretroviral therapy (ART) nephrotoxicity. Immediate ART initiation reduces mortality and is now the standard of care, but the long-term impact of prolonged ART exposure on CKD is unknown. To evaluate this, the Strategic Timing of Antiretroviral Treatment (START) trial randomized 4,684 ART-naïve adults with CD4 cell count under 500 cells/mm to immediate versus deferred ART.
View Article and Find Full Text PDF